E.V. DYAKOVA², N.S. SPIRIDONOVA², L.I. MINGAZOVA², S.R. NIZAMOVA², N.G. SHAMSUTDINOVA^1, 2, E.R. KIRILLOVA^1, 2, D.M. GAYSINA¹, A.M. FATYKHOVA¹, D.I. ABDULGANIEVA^1, 2

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

  Contact details:

Shamsutdinova N.G. — PhD (medicine), Assistant Lecturer of the Department of Hospital Therapy

Address: 36 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: ngshamsutdinova@gmail.com

The purpose — to assess the severity of cognitive deficit in patients with previous COVID-19.

Material and methods. We examined 20 patients after COVID-19 hospitalized in the Pulmonology Department of Republic Clinical Hospital of the Republic of Tatarstan. All patients underwent general clinical and laboratory examination, computed tomography of the lungs, and tests with a 6-minute walk. To assess the severity of dyspnea, we used the MMRS questionnaire and the Borg scale. We used the Montreal Cognitive Assessment Scale (MoCA), the Mini-Cog test, and the MMSE to identify cognitive functions.

Results. After analyzing the data of patients with mild severity (CT 1), we found that cognitive functions and the volume of lung lesions did not have a significant relationship. In patients with large lung lesions (CT 2–4), there was a correlation between the detection rate and the percentage of frosted glass detection on the one hand and the results of the MiniCog test, on the other (r = -0,69 and r = -0,93). Also, in this group of patients, we found a strong positive correlation (r = -0,8) between the frosted glass ratio and the Borg score at rest. It shows that patients with smaller changes in the lungs assess the dyspnea severity more correctly.

Conclusion. Patients after COVID-19 have cognitive impairments of varying severity. In the group of patients with more severe lung damage (CT 2–4), there are changes in cognitive functions that correlate with the functional status of the patient.

Key words: COVID-19, coronavirus infection, SARS-CoV-2, cognitive impairments, cognitive dysfunction.

REFERENCES

1. Mao L., Jin H., Wang M. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol., 2020, pp. 1–5.
2. Pinna P., Grewal P., Hall J.P., Tavarez T., Dafer R.M., Garg R., Osteraas N.D., Pellack D.R., Asthana A., Fegan K., Patel V., Conners J.J., John S., Silva I.D. Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. Journal of the neurological sciences, 2020, vol. 415, p. 116969. DOI: 10.1016/j.jns.2020.116969
3. https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-following-acute-viral-illness?sectionName=Persistent%20symptoms&search=postcovid&topicRef=128153&anchor=H2189549345&source=see_link#H2189549345 (accessed on: 30.03.2021).
4. Mazza M.G., Palladini M., De Lorenzo R. et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain, Behavior and Immunity, 2021. ISSN 0889-1591, DOI: 10.1016/j.bbi.2021.02.021
5. Jamoussi A., Ferchichi M., Ayed S et al. Séquelles psycho-cognitives et altération de la qualité de vie chez les survivants de la COVID 19 enréanimation: un risqueréel. Revue des Maladies Respiratoires Actualités, 2021, vol. 13, issue 1, p. 38. ISSN 1877-1203, DOI: 10.1016/j.rmra.2020.11.065
6. Polascik B., Browndyke J., Davis S., Liu A. Cognitive consequences of COVID-19 in older adults with cognitive impairment. The American Journal of Geriatric Psychiatry. Pub Date: 2021-03-16. DOI: 1016/j.jagp.2021.01.066
7. Navarra-Ventura G., López-Aguilar J., Blanch L., Fernandez-Gonzalo S. Characterization and management of cognitive and emotional alterations in COVID-19 critically ill patients after ICU discharge. Med Intensiva, 2020, Dec 7. S0210-5691(20)30345-4. DOI: 10.1016/j.medin.2020.11.004. Epub ahead of print. PMID: 33441245; PMCID: PMC7721351.
8. Almeria M., Cejudo J.C., Sotoca J., Deus J., Krupinski J. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health., 2020, Dec., vol. 9, p. 100163. DOI: 10.1016/j.bbih.2020.100163 Epub 2020 Oct 22. PMID: 33111132; PMCID: PMC7581383.
9. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term. Alz Res Therapy, 2020, vol. 12, p. 170. DOI: 10.1186/s13195-020-00744-w
10. Yesilkaya U.H., Sen M., Balcioglu Y.H. COVID-19-related cognitive dysfunction may be associated with transient disruption in the DLPFC glutamatergic pathway. Journal of Clinical Neuroscience, 2021.